Premium
Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability
Author(s) -
Umeda Yuzo,
Nagasaka Takeshi,
Mori Yoshiko,
Sadamori Hiroshi,
Sun DongSheng,
Shinoura Susumu,
Yoshida Ryuich,
Satoh Daisuke,
Nobuoka Daisuke,
Utsumi Masashi,
Yoshida Kazuhiro,
Yagi Takahito,
Fujiwara Toshiyoshi
Publication year - 2013
Publication title -
journal of hepato‐biliary‐pancreatic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 1868-6974
DOI - 10.1007/s00534-012-0531-9
Subject(s) - kras , microsatellite instability , medicine , colorectal cancer , oncology , cohort , metastasis , cancer research , mutation , cancer , microsatellite , gene , biology , allele , genetics
Background The discovery of practical biomarkers is important to realize personalized medicine for patients with malignant neoplasias, including colorectal cancer (CRC). Purpose The aim of this study was to determine reliable prognostic biomarkers by the analysis of patients with resectable colorectal liver metastases (CRLM). Methods Genomic DNA was obtained from the CRLM tissues of a cohort of 126 patients with CRLM with curative hepatic resection. The KRAS / BRAF mutation spectrum and microsatellite instability (MSI) status were successfully analyzed in 100 of the 126 CRLM tissues and these findings were examined in relation to the patients' clinical outcomes. Results The cohort of 100 CRLM patients consisted of 46 with synchronous and 54 with metachronous liver metastasis. Overall survival and disease‐free survival at 5 years were 57.4 and 24.9 %, respectively. MSI analysis revealed that none of the 100 CRLM specimens showed any evidence of MSI. By KRAS/BRAF mutation analysis, the analyzed CRLM patients were divided into 3 groups; KRAS ‐mutant ( KRAS ‐Mt; n = 27), BRAF ‐mutant ( BRAF ‐Mt; n = 3), and wild‐types of both genes (Wild‐type; n = 70). In the survival analysis, both KRAS ‐Mt and BRAF ‐Mt patients showed significantly poorer prognoses compared with Wild‐type patients. Furthermore, although the population with the BRAF mutation was small, this mutation had a significant negative impact on disease‐free survival. Conclusions In this study, all tumors in the cohort of CRLM patients were non‐MSI tumors, suggesting MSI cancer in primary CRC would rarely reveal metastatic potential. KRAS and BRAF mutations are suggested to be poor prognostic factors in CRLM. Genetic information has an essential role as a prognostic marker and could contribute to the decisions on treatment strategy for CRLM.